<DOC>
	<DOCNO>NCT00196937</DOCNO>
	<brief_summary>Infection human papillomavirus ( HPV ) clearly establish central cause cervical cancer . Indeed , certain oncogenic type HPV infect cervix ( part uterus womb ) . This infection may go away , go away ( call persistent infection ) , lead woman long period time cancer cervix . This study evaluate immunogenicity safety GSK Biologicals HPV-16/18 vaccine 12 month , woman 55 year age study start . Approximately 660 study subject receive HPV vaccine administer intramuscularly accord 0-1-6 month schedule . The study extend assess long-term safety immunogenicity HPV-16/18 vaccine . The Protocol Posting update order comply FDA Amendment Act , Sep 2007 .</brief_summary>
	<brief_title>Human Papilloma Virus ( HPV ) Vaccine Immunogenicity Safety Trial Young Adult Women With GSK Biologicals ' HPV-16/18</brief_title>
	<detailed_description />
	<mesh_term>Vaccines</mesh_term>
	<criteria>Inclusion criterion primary study : A woman investigator believe and/or parents/legally acceptable representative comply requirement protocol . A woman , include , 15 55 year age time first vaccination . Written inform consent obtain subject prior enrolment ( subject legal age consent , write informed consent must obtain parent legally acceptable representative , addition , subject sign personally date write informed assent ) . Free obvious health problem . Subject must negative urine pregnancy test . Subject must nonchildbearing potential , childbearing potential , must abstinent must use adequate contraceptive precaution 30 day prior vaccination must agree continue precaution two month completion vaccination series . Subjects reach menarche study therefore become childbearing potential must agree follow precaution Inclusion criterion extension study A female enrol primary study receive three dos vaccine . Written inform consent obtain subject prior enrolment ( subject legal age consent , write informed consent must obtain parent legally acceptable representative , addition , subject must sign personally date write informed assent ) . Exclusion criterion primary study : Pregnant breastfeeding . A woman plan become pregnant , likely become pregnant ( determined investigator ) planning discontinue contraceptive precaution study period , two month last vaccine dose . Use investigational nonregistered product ( drug vaccine ) study vaccine within 30 day precede first dose study vaccine , plan use study period ( Month 12 ) . Chronic administration immunosuppressant immunemodifying drug within six month prior first vaccine dose , plan administration study period . Planned administration/administration vaccine foreseen study protocol within 30 day 30 day first dose study vaccine . Planned administration/administration routine vaccine 8 day first dose study vaccine allow . Enrolment defer subject outside specify window . Previous administration component investigational vaccine Previous vaccination HPV . Any medically diagnose suspected immunodeficient condition base medical history physical examination . History allergic disease , suspect allergy reaction likely exacerbate component study vaccine . Hypersensitivity latex . Known acute chronic , clinically significant neurologic , hepatic renal functional abnormality , determine previous physical examination laboratory test . History chronic condition ( ) require treatment . Administration immunoglobulins and/or blood product within 3 month precede first dose study vaccine plan administration study period . Enrolment defer subject outside specify window . Acute disease time enrolment . Exclusion criterion extension study Use investigational nonregistered product ( drug vaccine ) plan use study period . Concurrently participate another clinical study , time study period , subject expose investigational noninvestigational product ( pharmaceutical product device ) . Chronic administration immunosuppressant immunemodifying drug occur less 3 month prior blood sampling . Administration immunoglobulins and/or blood product within three month precede blood sampling .</criteria>
	<gender>Female</gender>
	<minimum_age>15 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>HPV Vaccine Safety</keyword>
</DOC>